Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Zovirax (00886157). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Acyclovir
Form:
18 of 18 products shown
13 general benefit · 5 not a benefit
Apo-Acyclovir · DIN 02207621 · 200 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Acyclovir · DIN 02207621
Manufacturer: Apotex Inc.; listing date 1998-12-31
Health Canada: Marketed since 1997-08-22 · brand APO-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Apotex inc · schedule Prescription
Apo-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.
Ministry pays: $0.3511 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02207621: Apo-Acyclovir
Raw flags: sec3=Y
Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id APX
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.3511; ministry $0.3511
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02207621
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43018Interchangeable products
Mint-Acyclovir · DIN 02524708 · $0.3511
Mylan-Acyclovir · DIN 02242784 · $0.3511
Teva-Acyclovir · DIN 02285959 · $0.3511
Zovirax · DIN 00634506 · not recorded
Shortage status: resolved shortage (ended February 8, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02207621
Shortage record checked October 6, 2026
Mint-Acyclovir · DIN 02524708 · 200 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Acyclovir · DIN 02524708
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2022-10-31
Health Canada: Marketed since 2022-07-15 · brand MINT-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.
Ministry pays: $0.3511 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02524708: Mint-Acyclovir
Raw flags: sec3=Y
Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id MIN
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.3511; ministry $0.3511
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524708
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101372Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511
Mylan-Acyclovir · DIN 02242784 · $0.3511
Teva-Acyclovir · DIN 02285959 · $0.3511
Zovirax · DIN 00634506 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524708
Shortage record checked October 6, 2026
Mylan-Acyclovir · DIN 02242784 · 200 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mylan-Acyclovir · DIN 02242784
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2001-06-07
Health Canada: Marketed since 2010-02-12 · brand MYLAN-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.
Ministry pays: $0.3511 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02242784: Mylan-Acyclovir
Raw flags: sec3=Y
Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id MYL
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.3511; ministry $0.3511
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242784
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66607Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511
Mint-Acyclovir · DIN 02524708 · $0.3511
Teva-Acyclovir · DIN 02285959 · $0.3511
Zovirax · DIN 00634506 · not recorded
Shortage status: active shortage (reported September 8, 2026, estimated to end December 8, 2026, last updated September 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242784
Shortage record checked October 6, 2026
Teva-Acyclovir · DIN 02285959 · 200 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Acyclovir · DIN 02285959
Manufacturer: Teva Canada Limited; listing date 2008-01-15
Health Canada: Marketed since 2011-01-25 · brand TEVA-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Teva canada limited · schedule Prescription
Teva-Acyclovir: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3511). What the ministry pays, not the patient.
Ministry pays: $0.3511 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02285959: Teva-Acyclovir
Raw flags: sec3=Y
Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id TEV
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.3511; ministry $0.3511
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285959
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77144Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511
Mint-Acyclovir · DIN 02524708 · $0.3511
Mylan-Acyclovir · DIN 02242784 · $0.3511
Zovirax · DIN 00634506 · not recorded
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285959
Shortage record checked October 6, 2026
Apo-Acyclovir · DIN 02207648 · 400 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Acyclovir · DIN 02207648
Manufacturer: Apotex Inc.; listing date 1998-12-31
Health Canada: Marketed since 1997-08-22 · brand APO-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Apotex inc · schedule Prescription
Apo-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.
Ministry pays: $0.8890 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02207648: Apo-Acyclovir
Raw flags: sec3=Y
Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id APX
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $0.8890; ministry $0.8890
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02207648
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43019Interchangeable products
Mint-Acyclovir · DIN 02524716 · $0.8890
Mylan-Acyclovir · DIN 02242463 · $0.8890
Teva-Acyclovir · DIN 02285967 · $0.8890
Zovirax · DIN 01911627 · not recorded
Shortage status: resolved shortage (ended October 10, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02207648
Shortage record checked October 6, 2026
Mint-Acyclovir · DIN 02524716 · 400 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Acyclovir · DIN 02524716
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2022-10-31
Health Canada: Marketed since 2022-07-15 · brand MINT-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.
Ministry pays: $0.8890 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02524716: Mint-Acyclovir
Raw flags: sec3=Y
Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id MIN
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $0.8890; ministry $0.8890
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524716
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101373Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890
Mylan-Acyclovir · DIN 02242463 · $0.8890
Teva-Acyclovir · DIN 02285967 · $0.8890
Zovirax · DIN 01911627 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524716
Shortage record checked October 6, 2026
Mylan-Acyclovir · DIN 02242463 · 400 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mylan-Acyclovir · DIN 02242463
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2001-06-07
Health Canada: Marketed since 2009-12-04 · brand MYLAN-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.
Ministry pays: $0.8890 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02242463: Mylan-Acyclovir
Raw flags: sec3=Y
Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id MYL
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $0.8890; ministry $0.8890
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242463
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66188Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890
Mint-Acyclovir · DIN 02524716 · $0.8890
Teva-Acyclovir · DIN 02285967 · $0.8890
Zovirax · DIN 01911627 · not recorded
Shortage status: anticipated shortage (last updated September 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242463
Shortage record checked October 6, 2026
Teva-Acyclovir · DIN 02285967 · 400 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Acyclovir · DIN 02285967
Manufacturer: Teva Canada Limited; listing date 2008-01-15
Health Canada: Marketed since 2011-01-25 · brand TEVA-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Teva canada limited · schedule Prescription
Teva-Acyclovir: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8890). What the ministry pays, not the patient.
Ministry pays: $0.8890 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02285967: Teva-Acyclovir
Raw flags: sec3=Y
Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id TEV
Source form: Tab; strength: 400mg
Recorded listing: General benefit
Source prices (unrounded): $0.8890; ministry $0.8890
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285967
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77145Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890
Mint-Acyclovir · DIN 02524716 · $0.8890
Mylan-Acyclovir · DIN 02242463 · $0.8890
Zovirax · DIN 01911627 · not recorded
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285967
Shortage record checked October 6, 2026
Apo-Acyclovir · DIN 02207656 · 800 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Acyclovir · DIN 02207656
Manufacturer: Apotex Inc.; listing date 1998-12-31
Health Canada: Marketed since 1997-08-22 · brand APO-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Apotex inc · schedule Prescription
Apo-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.
Ministry pays: $1.2673 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02207656: Apo-Acyclovir
Raw flags: sec3=Y
Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id APX
Source form: Tab; strength: 800mg
Recorded listing: General benefit
Source prices (unrounded): $1.2673; ministry $1.2673
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02207656
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43020Interchangeable products
Mint-Acyclovir · DIN 02524724 · $1.2673
Mylan-Acyclovir · DIN 02242464 · $1.2673
Teva-Acyclovir · DIN 02285975 · $1.2673
Zovirax · DIN 01911635 · $1.2673
Shortage status: resolved shortage (ended February 8, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02207656
Shortage record checked October 6, 2026
Mint-Acyclovir · DIN 02524724 · 800 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Acyclovir · DIN 02524724
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2022-10-31
Health Canada: Marketed since 2022-07-15 · brand MINT-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.
Ministry pays: $1.2673 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02524724: Mint-Acyclovir
Raw flags: sec3=Y
Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id MIN
Source form: Tab; strength: 800mg
Recorded listing: General benefit
Source prices (unrounded): $1.2673; ministry $1.2673
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524724
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101374Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673
Mylan-Acyclovir · DIN 02242464 · $1.2673
Teva-Acyclovir · DIN 02285975 · $1.2673
Zovirax · DIN 01911635 · $1.2673
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524724
Shortage record checked October 6, 2026
Mylan-Acyclovir · DIN 02242464 · 800 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Acyclovir · DIN 02242464
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2001-03-07
Health Canada: Marketed since 2009-12-04 · brand MYLAN-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.
Ministry pays: $1.2673 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02242464: Mylan-Acyclovir
Raw flags: sec3=Y
Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id MYL
Source form: Tab; strength: 800mg
Recorded listing: General benefit
Source prices (unrounded): $1.2673; ministry $1.2673
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242464
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66189Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673
Mint-Acyclovir · DIN 02524724 · $1.2673
Teva-Acyclovir · DIN 02285975 · $1.2673
Zovirax · DIN 01911635 · $1.2673
Shortage status: resolved shortage (ended May 26, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242464
Shortage record checked October 6, 2026
Teva-Acyclovir · DIN 02285975 · 800 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Acyclovir · DIN 02285975
Manufacturer: Teva Canada Limited; listing date 2007-01-02
Health Canada: Marketed since 2011-01-25 · brand TEVA-ACYCLOVIR · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Teva canada limited · schedule Prescription
Teva-Acyclovir: Formulary list price $1.27 per unit (the source does not state the unit; exact figure $1.2673). What the ministry pays, not the patient.
Ministry pays: $1.2673 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02285975: Teva-Acyclovir
Raw flags: sec3=Y
Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id TEV
Source form: Tab; strength: 800mg
Recorded listing: General benefit
Source prices (unrounded): $1.2673; ministry $1.2673
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285975
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77146Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673
Mint-Acyclovir · DIN 02524724 · $1.2673
Mylan-Acyclovir · DIN 02242464 · $1.2673
Zovirax · DIN 01911635 · $1.2673
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285975
Shortage record checked October 6, 2026
Apo-Acyclovir Ointment · DIN 02477130 · 5% · Top Oint
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Acyclovir Ointment · DIN 02477130
Manufacturer: Apotex Inc.; listing date 2019-05-31
Health Canada: Marketed since 2019-03-14 · brand APO-ACYCLOVIR OINTMENT · ATC D06BB03 ACICLOVIR · form Ointment · route Topical · ingredients ACYCLOVIR 5 %/W/W · company Apotex inc · schedule Prescription
DIN 02477130: Apo-Acyclovir Ointment
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840406002; group id 816; item number 1995; lccId None; manufacturer id APX
Source form: Top Oint; strength: 5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $12.3114; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477130
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96789Interchangeable products
Taro-Acyclovir · DIN 02522306 · not recorded
Zovirax · DIN 00569771 · not recorded
Shortage status: resolved shortage (ended August 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477130
Shortage record checked October 6, 2026
Taro-Acyclovir · DIN 02522306 · 5% · Top Oint
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Taro-Acyclovir · DIN 02522306
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-04-29
Health Canada: Marketed since 2022-02-25 · brand TARO-ACYCLOVIR · ATC D06BB03 ACICLOVIR · form Ointment · route Topical · ingredients ACYCLOVIR 5 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
DIN 02522306: Taro-Acyclovir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840406002; group id 816; item number 1995; lccId None; manufacturer id TAR
Source form: Top Oint; strength: 5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $12.3114; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02522306
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101144Interchangeable products
Apo-Acyclovir Ointment · DIN 02477130 · not recorded
Zovirax · DIN 00569771 · not recorded
Shortage status: resolved shortage (ended June 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522306
Shortage record checked October 6, 2026
Zovirax · DIN 00569771 · 5% · Top Oint
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 00569771
Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01
Health Canada: Marketed since 2020-12-22 · brand ZOVIRAX · ATC D06BB03 ACICLOVIR · form Ointment · route Topical · ingredients ACYCLOVIR 5 %/W/W · company Bausch health, canada inc. · schedule Prescription
DIN 00569771: Zovirax
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840406002; group id 816; item number 1995; lccId None; manufacturer id VAL
Source form: Top Oint; strength: 5%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00569771
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4959Interchangeable products
Apo-Acyclovir Ointment · DIN 02477130 · not recorded
Taro-Acyclovir · DIN 02522306 · not recorded
Shortage status: resolved shortage (ended August 10, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00569771
Shortage record checked October 6, 2026
Zovirax · DIN 01911635 · 800 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2011-08-03 — choose a marketed DIN from the same-category list.Discontinued August 3, 2011 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2011-08-03 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2011-08-03 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 01911635
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01
Health Canada: Cancelled post market since 2011-08-03 · brand ZOVIRAX 800 · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 800 MG · company Glaxosmithkline inc · schedule Prescription
DIN 01911635: Zovirax
Raw flags: sec3=Y
Item: 081800002; group id 62; item number 0124; lccId None; manufacturer id GSK
Source form: Tab; strength: 800mg
Recorded listing: General benefit
Source prices (unrounded): $5.0692; ministry $1.2673
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01911635
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11632Interchangeable products
Apo-Acyclovir · DIN 02207656 · $1.2673
Mint-Acyclovir · DIN 02524724 · $1.2673
Mylan-Acyclovir · DIN 02242464 · $1.2673
Teva-Acyclovir · DIN 02285975 · $1.2673
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01911635
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 3, 2011 — choose a marketed DIN from the same-category list.
Zovirax · DIN 00634506 · 200 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-01-11 — choose a marketed DIN from the same-category list.Discontinued January 11, 2016 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-01-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-01-11 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 00634506
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01
Health Canada: Cancelled post market since 2016-01-11 · brand ZOVIRAX TAB 200MG · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 200 MG · company Glaxosmithkline inc · schedule Prescription
DIN 00634506: Zovirax
Raw flags: notABenefit=Y, sec3=Y
Item: 081800100; group id 62; item number 0122; lccId None; manufacturer id GSK
Source form: Tab; strength: 200mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00634506
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7063Interchangeable products
Apo-Acyclovir · DIN 02207621 · $0.3511
Mint-Acyclovir · DIN 02524708 · $0.3511
Mylan-Acyclovir · DIN 02242784 · $0.3511
Teva-Acyclovir · DIN 02285959 · $0.3511
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00634506
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 11, 2016 — choose a marketed DIN from the same-category list.
Zovirax · DIN 01911627 · 400 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-20 — choose a marketed DIN from the same-category list.Discontinued February 20, 2014 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-20 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-02-20 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: innoviCares lists Zovirax (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Zovirax · DIN 01911627
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01
Health Canada: Cancelled post market since 2014-02-20 · brand ZOVIRAX 400 · ATC J05AB01 ACYCLOVIR · form Tablet · route Oral · ingredients ACYCLOVIR 400 MG · company Glaxosmithkline inc · schedule Prescription
DIN 01911627: Zovirax
Raw flags: notABenefit=Y, sec3=Y
Item: 081800101; group id 62; item number 0123; lccId None; manufacturer id GSK
Source form: Tab; strength: 400mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01911627
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11420Interchangeable products
Apo-Acyclovir · DIN 02207648 · $0.8890
Mint-Acyclovir · DIN 02524716 · $0.8890
Mylan-Acyclovir · DIN 02242463 · $0.8890
Teva-Acyclovir · DIN 02285967 · $0.8890
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01911627
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 20, 2014 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (D06BB, J05A, J05AB): coverage varies; not interchangeable
Ganciclovir (Cytovene): general benefit
Famciclovir (Famvir): limited Use 147, not a benefit
Remdesivir (Veklury): limited Use 722
Valganciclovir (Valcyte): limited Use 374, 568, 569, limited Use 571, 572, 573
Imiquimod (Taro-Imiquimod Pump): not a benefit
Abacavir + lamivudine + zidovudine (Trizivir): general benefit
50 more in the class list below
Valacyclovir
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Apo-Valacyclovir · DIN 02295822 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Valacyclovir · DIN 02295822
Manufacturer: Apotex Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-05-23 · brand APO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Apotex inc · schedule Prescription
Apo-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02295822: Apo-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id APX
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295822
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78118Interchangeable products
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: shortage reported ended July 23, 2026 (report last updated July 23, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295822
Shortage record checked October 6, 2026
Auro-Valacyclovir · DIN 02405040 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Valacyclovir · DIN 02405040
Manufacturer: Auro Pharma Inc.; listing date 2013-07-30
Health Canada: Marketed since 2015-07-24 · brand AURO-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Auro pharma inc · schedule Prescription
Auro-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02405040: Auro-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id AUR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02405040
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88988Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended August 30, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405040
Shortage record checked October 6, 2026
Jamp Valacyclovir · DIN 02440598 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Valacyclovir · DIN 02440598
Manufacturer: Jamp Pharma Corporation; listing date 2021-07-30
Health Canada: Marketed since 2021-04-13 · brand JAMP VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Jamp pharma corporation · schedule Prescription
Jamp Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02440598: Jamp Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id JPC
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02440598
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92496Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02440598
Shortage record checked October 6, 2026
Mylan-Valacyclovir · DIN 02351579 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Valacyclovir · DIN 02351579
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2010-07-20
Health Canada: Marketed since 2010-05-25 · brand MYLAN-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02351579: Mylan-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id MYL
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02351579
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83683Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended April 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02351579
Shortage record checked October 6, 2026
PMS-Valacyclovir · DIN 02298457 · 500 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Valacyclovir · DIN 02298457
Manufacturer: Pharmascience Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-05-16 · brand PMS-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Pharmascience inc · schedule Prescription
PMS-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02298457: PMS-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id PMS
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298457
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78376Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
Riva-Valacyclovir · DIN 02316447 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended September 11, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298457
Shortage record checked October 6, 2026
Riva-Valacyclovir · DIN 02316447 · 500 mg · tablet
General benefitMarketed · checked November 17, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Valacyclovir · DIN 02316447
Manufacturer: Laboratoire Riva Inc.; listing date 2025-08-29
Health Canada: Marketed since 2008-10-27 · brand RIVA-VALACYCLOVIR · ATC J05AB11 VALACICLOVIR · form Tablet · route Oral · ingredients VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500 MG · company Laboratoire riva inc. · schedule Prescription
Riva-Valacyclovir: Formulary list price $0.62 per unit (the source does not state the unit; exact figure $0.6198). What the ministry pays, not the patient.
Ministry pays: $0.6198 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02316447: Riva-Valacyclovir
Raw flags: sec3=Y
Item: 081800012; group id 114; item number 0196; lccId None; manufacturer id RIA
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.6198; ministry $0.6198
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02316447
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80195Interchangeable products
Apo-Valacyclovir · DIN 02295822 · $0.6198
Auro-Valacyclovir · DIN 02405040 · $0.6198
Co Valacyclovir · DIN 02331748 · $0.6198
Jamp Valacyclovir · DIN 02440598 · $0.6198
Jamp-Valacyclovir · DIN 02441454 · $0.6198
Mylan-Valacyclovir · DIN 02351579 · $0.6198
PMS-Valacyclovir · DIN 02298457 · $0.6198
Sandoz Valacyclovir · DIN 02347091 · $0.6198
Teva-Valacyclovir · DIN 02357534 · $0.6198
Valacyclovir · DIN 02442000 · $0.6198
Valacyclovir · DIN 02454645 · $0.6198
Valtrex · DIN 02219492 · $0.6198
Shortage status: resolved shortage (ended January 17, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02316447
Shortage record checked October 6, 2026
Other products in the same Health Canada class (D06BB, J05A, J05AB): coverage varies; not interchangeable
Ganciclovir (Cytovene): general benefit
Famciclovir (Famvir): limited Use 147, not a benefit
Remdesivir (Veklury): limited Use 722
Valganciclovir (Valcyte): limited Use 374, 568, 569, limited Use 571, 572, 573
Imiquimod (Taro-Imiquimod Pump): not a benefit
Abacavir + lamivudine + zidovudine (Trizivir): general benefit
50 more in the class list below
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered
· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:04
and 53 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.Other drugs whose Health Canada label lists a similar indication: herpes zoster
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
FAMCICLOVIR · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 147 (2)
INDICATIONS AND CLINICAL USE
FAMVIR® (famciclovir) tablets are indicated :
• for the treatment of acute herpes zoster (shingles)
• for the treatment or suppression of recurrent episodes of genital herpes in
immunocompetent adults.
PM: https://pdf.hres.ca/dpd_pm/00078599.PDF; date FEB 13, 2025; DIN 02177102; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
Zovirax (acyclovir 5%) cream is indicated for the topical management of initial episodes of
genital herpes simplex infections. The prophylactic use of this preparation has not been
established.
Zovirax (acyclovir 5%) ointment is for the management of initial episodes of genital herpes
simplex infections. It is also indicated in the management of non-life-threatening cutaneous
herpes simplex virus infections in immunocompromised patients. The prophylactic use of this
preparation has not been established.
Pr
ZOVIRAX ® Product Monograph Page 2 of 32
In the treatment of genital herpes, appropriate examinations should be performed to rule out other
sexually transmitted diseases. Therapy should begin as early as possible after the start of an
infection.
Whereas cutaneous lesions associated with herpes simplex infections are often pathognomonic,
TZANCK smears prepared from lesion exudate or scrapings may assist in the diagnosis. Positive
cultures for herpes simplex virus offer the only absolute means for confirmation of the diagnosis.
These indications are based on …
https://pdf.hres.ca/dpd_pm/00059349.PDF
PM date: December 22, 2020
Source product: ZOVIRAX; DIN 00569771; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications
VALTREX, valacyclovir tablets (as valacyclovir hydrochloride), is indicated:
• For the treatment of herpes zoster (shingles) in adult patients.
• For the treatment or suppression of genital herpes in immunocompetent adult patients and for the
suppression of recurrent genital herpes in HIV infected adult patients.
• To reduce the risk of transmission of genital herpes with the use of suppressive therapy in adult
patients. Safer sex practices should be used with suppressive therapy.
• For the treatment of cold sores (herpes labialis) in adult patients and adolescent patients ≥ 12 years
of age.
1.1. Pediatrics
Pediatrics (<12 years of age): No data are available to Health Canada; therefore, Health Canada has not
authorized an indication for pediatric use.
1.2. Geriatrics
Geriatrics (>65 years of age): Use in the geriatric population may be associated with differences in
safety due to age-related changes in renal function and a brief discussion can be found in the
appropriate sections (see 7.Warnings and Precautions, Renal)
https://pdf.hres.ca/dpd_pm/00083875.PDF
PM date: 2026-03-13
Source product: VALTREX; DIN 02219492; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Mylan-Acyclovir · DIN 02242784
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-12-08, last updated 2026-09-09); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242784
Teva-Acyclovir · DIN 02285959
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285959
Teva-Acyclovir · DIN 02285967
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285967
Teva-Acyclovir · DIN 02285975
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285975
Apo-Valacyclovir · DIN 02295822
Shortage status: shortage reported ended 2026-07-23 (report last updated 2026-07-23); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295822
For Apo-Acyclovir Ointment, Taro-Acyclovir, Zovirax: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.